Earlier this month, Revance Therapeutics Inc (NASDAQ: RVNC) named Mark Foley as its new CEO.
The addition of a commercial-focused CEO, with experience in unlocking shareholder value in aesthetics, is a “major positive,” according to Wells Fargo.
Wells Fargo’s Jacob Hughes upgraded Revance Therapeutics from Market Perform to Outperform raising the price target from $12.50 to $20.
Mark Foley’s strong track record of commercial success in aesthetics is particularly important, as Revance Therapeutics is transitioning from a development stage to commercialization, Hughes said in the upgrade note.
He added that the new CEO will also focus on reducing the company’s operating expenses to curb the rate of cash burn.
Hughes mentioned that Revance Therapeutics had several catalysts over the next six to twelve months, the most notable of which is a biologics license application (BLA) submission for DaxibotulinumtoxinA (DAXI) for treatment of glabellar lines by the end of November.
“Revance growth potential is significant in a multi-billion neurotoxins market, targeting both aesthetic and therapeutic indications,” the analyst wrote. He added that these markets were poised for continued expansion and that disruption from the merger between Allergan plc (NYSE: AGN) and AbbVie Inc (NYSE: ABBV) could create opportunities to take share.
Shares of Revance Therapeutics rose slightly to close trading at $15.42 on Tuesday.
Latest Ratings for RVNC
|Oct 2019||Upgrades||Market Perform||Outperform|
|Jun 2019||Initiates Coverage On||Overweight|
|Feb 2019||Initiates Coverage On||Market Perform|
View More Analyst Ratings for RVNC
View the Latest Analyst Ratings
See more from Benzinga
- Analysts Remain Bullish On NXP Semiconductors Despite Mixed Guidance
- BMO Waits On The Sidelines For Better Momentum At Check Point Software
- Bank Of America Sees Buying Opportunity In Atlassian
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.